Acasti Pharma shareholders approve continuance to BC, domestication to Delaware, and 2024 equity plan

Grace Therapeutics, Inc.

Shareholders approved continuance from Quebec to British Columbia (5,874,491 For, 71,931 Against, 8,683 Abstain).
Shareholders approved domestication from British Columbia to Delaware (5,891,584 For, 54,366 Against, 9,155 Abstain).
Shareholders approved the 2024 Equity Incentive Plan (5,832,903 For, 86,289 Against, 35,913 Abstain).
All five director nominees were elected; KPMG ratified as auditor (7,055,362 For).
Advisory vote on named executive officer compensation passed (5,685,429 For, 98,138 Against).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.